STRATEGIES FOR STUDYING BRAIN DISORDERS

Vol.8 Implications of Comorbidity for Etiology and Treatment of Neuropsychiatric Disorders

Vol.8 Implications of Comorbidity for Etiology and Treatment of Neuropsychiatric Disorders

Editors:Tomás Palomo, Richard J. Beninger, Trevor Archer, Richard M. Kostrzewa

June 2007

Publisher: Editorial CYM, General Oráa, 47, 28006 MADRID

ISBN: 978-84-934250-0-5

Pages: 698

Congresess

Implications of Comorbidity for Etiology and Treatment of Neuropsychiatric Disorders

Mazagón (Huelva)

October 19 - 23 2005

The content of this congress, together with other contributions on the topic, are collected in vol. 8 of the series "Strategies for studying brain disorders"

PROGRAMME

  • Tomas Palomo, Spain
    Opening Remarks
  • German Berrios, UK.
    Comorbidity and Psychiatric Nosology

S1. GENETIC VARIATION UNDERLYING COMORBIDITY

  • Douglas Blackwood, UK
    Common Genotypes in Schizophrenia and Depression
  • Janet Hoenicka, Spain
    Genetic variants in Psychiatric Disorders
  • Kenneth Blum, USA
    Genetic Variants underlying Reward Deficiency Syndrome
  • Tomás Palomo, Spain
    Genetic Contributions to Psychopathic Traits in Alcoholic Patients
  • Isidro Ferrer, Spain
    DNA chip technology in Brain Banks: Efficiency and Reliability for Neuropsychiatric Research

S2. NEURONAL SUBSTRATES OF COMORBIDITY IN ANIMAL MODELS

  • Susan Totterdell, UK
    The Anatomy of Synaptic Interactions in Cortical and Limbic Regions
  • Bita Moghaddam, USA
    Shared Pathways that support Addictive and Schizophrenia –like Behaviors
  • Athina Markou, USA
    Design of Animal Models and Treatments for Addiction and Depression Comorbidity
  • Peter Kalivas, UK
    Signal Transduction Mechanisms in Addiction and Schizophrenia
  • Mark Geyer, USA
    The Family of Sensorimotor Gating Disorders: Comorbidities or Diagnostic Overlaps?
  • Therese M. Jay, France
    Stress, Frontal Synaptic Plasticity and Psychotropic Drugs

S3. MOVEMENT DISORDERS IN PSYCHOTIC STATES

  • Trevor Archer, Sweden
    Postnatal Iron Involvement in Motor Alterations pertaining to Psychosis-related Behaviour
  • Peter Riederer, Germany
    Psychotics Stages in Parkinson´s Disease and Motor Symptoms in Schizophrenia: Basic Aspects
  • Moussa Youdim, Israel
    Implications of Comorbidity for Etiology and Treament of Neurodegenerative Diseases with Multifunctional Drugs
  • Werner Schmidt, Germany
    Behavioural Sensitization in Schizophrenia,Parkinson´s Disease and Dyskinesia

S4. IATROGENIC COMORBIDITY

  • Richard J. Beninger, Canada
    Cognitive Effects of Antipsychotic Medications
  • Michael Maes, Belgium
    Immunological Effects of Antipsychotics
  • Richard M. Kostrzewa , USA
    Haloperidol-Induced Tardive Dyskinesia inRats, its Persistence after Discontinuation of Haloperidol, and Effective Treatments
  • Abraham Weizman, Israel
    Comorbidity of Schizophrenia and OCD: Clinical Aspects, Neurobiology and Treatment

S5. COGNITION LEARNING AND COMORBIDITY

  • Klaus Ebmeier, UK
    Cognitive Impairment in Major Depression (the fMRI perspective)?
  • Brian Leonard, Ireland
    Changes in the Immune System in Depression and Dementia: Causal o Coincidental Effects?
  • José María Delgado, Spain
    Experimental models for the Study of Cognitive Disorders
  • Martín Cammarota, Brazil
    The consequences of Memory Expression
  • Ivan Izquierdo, Brazil
    Further Learning moves Memory making Mechanisms from the Hippocampus to the Striatum

S6. COMORBIDITY IN ADDICTION WITH OTHER PSYCHIATRIC ILLNESSES

  • Marta Torres, Spain
    Importance of Clinical Diagnoses for Comorbidity studies
  • John Krystal, USA
    Comorbidity between Schizophrenia and Addiction
  • Pierre Sokoloff, France
    BDNF: an Etiological Factor in Schizophrenia and Drug Addiction
  • Alan I. Green, USA
    Pharmacotherapy for Schizophrenia and Co-occurring Substance Use Disorders
  • Miguel Casas, Spain
    Dual Diagnosys in Physicians
  • Cristine Barrowclough, UK
    Psychological Approaches to working with Psychosis and Substance Misusing Clients

S7. IMPLICATIONS OF COMORBIDITY FOR ETIOLOGY AND TREATMENT OF NEUROPSYCHIATRIC DISORDERS

  • Antonio Lobo, Spain
    Depressive Comorbidity in patients with Somatic Pathology
  • Henry Szechtman, Canada
    Obsessive-compulsive Disorder as a Disturbance of Security Motivation. The Immune function in Schizophrenia
  • Vicente Molina, Spain
    Neuroimaging Profiles, Typical and Atypical Antipsychotics and Disease Evolution
  • Tom G. Bolwig, Denmark
    Epilepsy and Affective Disorder
  • Norbert Müller, Germany
    The Immune function in Schizophrenia
  • Anthony Grace, USA
    Disruption of Cortical-Amygdala Interaction as a substrate for Co-morbidtity
  • Joseph T. Coyle, USA
    Glutamate Transmission as a Common Mechanism in Co-morbid Psycopathologies
  • Tomás Palomo, Spain
    Concluding Remarks

Fundación Cerebro y Mente
c/ General Oraa, 47 - 1º E 28006 Madrid, España
Telf: +34 91 561 1267 Fax: +34 91 564 1817
http://www.cermente.com

Resolución mínima: 1024 x 768. Navegadores recomendados: Google Chrome / Firefox 3.5+ / Internet Explorer 9.0+ / Opera 9.0+ / Safari 3.0+